Mass Spec Meets Oncology | GenomeWeb

Mass Spec Meets Oncology

Premium

By William Langbein

 

Since the 1990s, monitoring biomarkers in the blood has been one of few noninvasive tools that an oncologist can use to diagnose cancer. Reliance on single biomarkers has been driven by a chemistry approach to research and wet lab technologies such as 2D gel electrophoresis — one antigen or protein can be isolated, characterized, and clinically linked to the presence of an invading tumor or cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.